In this study, the combination of olanzapine and valproic acid was associated with a more significant reduction in IL-1 and TNF-α levels, and an increase in IL-10, compared to olanzapine monotherapy.[27,28] These changes indicate a potential anti-inflammatory effect of the combination therapy, which may help to reduce neuroinflammation and improve long-term outcomes in BD. Here, IL10 is linked to Behcet disease.